ROME Therapeutics
ROME Therapeutics is pioneering a new approach to treating serious diseases by illuminating the dark genome, which consists of vast regions of underexplored genetic material. The company focuses on developing novel therapies for cancer and autoimmune diseases, leveraging insights from the dark genome to create breakthrough treatments. Their lead program targets LINE-1 reverse transcriptase, a protein linked to various diseases, including autoimmune disorders and cancer. ROME's world-class team combines expertise in oncology, immunology, machine learning, and virology, positioning the company as a leader in this innovative field.
ROME Therapeutics
ROME Therapeutics is pioneering a new approach to treating serious diseases by illuminating the dark genome, which consists of vast regions of underexplored genetic material. The company focuses on developing novel therapies for cancer and autoimmune diseases, leveraging insights from the dark genome to create breakthrough treatments. Their lead program targets LINE-1 reverse transcriptase, a protein linked to various diseases, including autoimmune disorders and cancer. ROME's world-class team combines expertise in oncology, immunology, machine learning, and virology, positioning the company as a leader in this innovative field.